Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
暂无分享，去创建一个
Francine E. Garrett-Bakelman | C. Mason | A. Melnick | K. Yen | R. Levine | P. Ward | C. Thompson | Cem Meydan | A. Intlekofer | A. Shih | K. Straley | E. Stein | K. Shank | C. Gliser | J. Travins | K. Knapp | Jacob L Glass | Camelia Gliser | J. Glass | Abbas Nazir | C. Thompson | Kristina M. Knapp